Clinical Trial Update: Safety, Tolerability, and Efficacy of mFOLFIRINOX ± BNT321 as Adjuvant Therapy Following Curative Resection in Patients With Pancreatic Adenocarcinoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating the safety, tolerability, and efficacy of the modified FOLFIRINOX regimen with or without BNT321 as adjuvant therapy after curative r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Adenocarcinoma
• Pancreatic Cancer

Drugs mentioned

• BNT321 (BNT321)
• mFOLFIRINOX

Snippet

Sponsor: BioNTech SE | Conditions: Pancreatic Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2025-10-31